These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26873482)

  • 1. Drug safety: withdrawn medications are only part of the picture.
    Rawson NS
    BMC Med; 2016 Feb; 14():28. PubMed ID: 26873482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
    Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
    Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Withdrawal Due to Safety: A Review of the Data Supporting Withdrawal Decision.
    Craveiro NS; Lopes BS; Tomás L; Almeida SF
    Curr Drug Saf; 2020; 15(1):4-12. PubMed ID: 31584381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems.
    Aronson JK
    Therapie; 2017 Oct; 72(5):555-561. PubMed ID: 28461037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
    Mendes D; Alves C; Batel Marques F
    Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
    McNaughton R; Huet G; Shakir S
    BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Drug Saf; 2017 May; 40(5):431-441. PubMed ID: 28238125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety surveillance of longitudinal databases: further methodological considerations.
    Schuemie MJ
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):670-2; author reply 673-5. PubMed ID: 22678687
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety surveillance of longitudinal databases: methodological considerations.
    Norén GN; Hopstadius J; Bate A; Edwards IR
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):714-7. PubMed ID: 21638520
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2016 Nov; 14(1):191. PubMed ID: 27894343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
    Ikeda J; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy.
    Lexchin J
    Br J Clin Pharmacol; 2015 May; 79(5):847-59. PubMed ID: 25393960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
    Lane S; Lynn E; Shakir S
    BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Is the Plural of a 'Yellow' Anecdote?
    Evans SJ
    Drug Saf; 2016 Jan; 39(1):1-3. PubMed ID: 26597283
    [No Abstract]   [Full Text] [Related]  

  • 16. New drug approval times and safety warnings in the United States and Canada, 1992-2011.
    Rawson NS
    J Popul Ther Clin Pharmacol; 2013; 20(2):e67-81. PubMed ID: 23650206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for safety signal detection in healthcare databases: a literature review.
    Arnaud M; Bégaud B; Thurin N; Moore N; Pariente A; Salvo F
    Expert Opin Drug Saf; 2017 Jun; 16(6):721-732. PubMed ID: 28490262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals.
    Arnaiz JA; Carné X; Riba N; Codina C; Ribas J; Trilla A
    Eur J Clin Pharmacol; 2001 Apr; 57(1):89-91. PubMed ID: 11372600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WITHDRAWN--a resource for withdrawn and discontinued drugs.
    Siramshetty VB; Nickel J; Omieczynski C; Gohlke BO; Drwal MN; Preissner R
    Nucleic Acids Res; 2016 Jan; 44(D1):D1080-6. PubMed ID: 26553801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study.
    de Bie S; Coloma PM; Ferrajolo C; Verhamme KM; Trifirò G; Schuemie MJ; Straus SM; Gini R; Herings R; Mazzaglia G; Picelli G; Ghirardi A; Pedersen L; Stricker BH; van der Lei J; Sturkenboom MC;
    Br J Clin Pharmacol; 2015 Aug; 80(2):304-14. PubMed ID: 25683723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.